

Gene Section

Mini Review

KIAA0101 (KIAA0101)

Shannon Joseph, Lingbo Hu, Fiona Simpson

University of Queensland Diamantina Institute, University of Queensland, Brisbane, Australia (SJ, LH, FS)

Published in Atlas Database: May 2011

Online updated version : <http://AtlasGeneticsOncology.org/Genes/KIAA0101D41058ch15q22.html>

DOI: 10.4267/2042/46054

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: FLJ58702; NS5ATP9; OEATC-1; OEATC1; PAF; p15(PAF); p15PAF

HGNC (Hugo): KIAA0101

Location: 15q22.31

DNA/RNA

Note

Murine gene embryonic expression shows highly restricted expression of KIAA0101 in facial prominences, limbs, somites, brain, spinal cord and hair follicles. It has a suggested role in embryonic development (van Beuren et al., 2007).

Description

The gene is composed of 4 exons.

Transcription

One transcript. RNA was expressed as a 1.1 kb message in liver, pancreas and placenta at high levels (Yu et al., 2001). RNA profiling shows it is highly expressed in a number of tumors, specifically in esophageal tumors, anaplastic thyroid carcinomas, pancreatic cancer and non-small-cell lung cancer lines (Yu et al., 2001;

Hosokawa et al., 2007). KIAA0101 was also reported to be down-regulated in colon cancer cells (Simpson et al., 2006) and human hepatocellular carcinoma (Guo et al., 2006). Nuclear protein NF-kappaB (p50) (Li et al., 2008), the Hepatitis C virus protein non-structural protein 5A (NS5A) (Shi et al., 2008) and ATF3 (Turchi et al., 2009) bind to the promoter region upstream of the KIAA0101 transcription initiation site promoting transcription in response to DNA damage.

Pseudogene

None.


Protein

Note


NS5ATP9, Hepatitis C virus NS5A-transactivated protein 9, HCV NS5A-transactivated protein 9, Overexpressed in anaplastic thyroid carcinoma-1, OEATC-1, OEATC1, p15(PAF), L5.

Description

The KIAA0101 gene encodes for a 111 amino acid 15 kDa protein. It contains a conserved proliferating cell nuclear antigen (PCNA)-binding motif (Yu et al., 2001).



DNA diagram. KIAA0101 9768 chr: 62444265-62460755. One transcript, 4 exons.



Protein diagram. 111 aa in length, single transcript, mutation I-A at position 65 and mutation F-A at position 68 results in loss of PCNA binding.

Expression

Predominant expression in liver, pancreas and brain. Not detected in heart or liver (Yu et al., 2001). The KIAA0101 protein was down-regulated in human hepatocellular carcinoma (Guo et al., 2006; Yuan et al., 2007). Increased protein levels have been detected in pancreatic cancer cells (Hosokawa et al., 2007).

Localisation

Nucleus, mitochondrion (Yu et al., 2001; Guo et al., 2006; Simpson et al., 2006; Yuan et al., 2007).

Function

The KIAA0101 protein binds to PCNA through a conserved PCNA binding domain. PCNA is required for DNA replication or repair as a supplementary factor for DNA polymerase (Paunesku et al., 2001). Proteins bound to PCNA can prevent its binding to DNA polymerase, in turn leading to inhibition of DNA synthesis, cell cycle progression and G1 cell cycle arrest (Yuan et al., 2007). PCNA binding proteins also interact with each other to modulate this regulation. For example, KIAA0101 also interacts in a complex with p33ING1 isoform 2, another PCNA binding protein which is a potential tumor suppressor and regulator of p53 (Simpson et al., 2006). UV irradiation caused increased association of KIAA0101 with PCNA suggesting that this association occurs in response to DNA damage. KIAA0101 also competes with p21WAF for binding to PCNA (Yu et al., 2001). KIAA0101 most recently been shown to act in concert with ATF3 to control genomic integrity after UV stress (Turchi et al., 2009). KIAA0101 expression levels are also regulated by NF-kappaB, this protein family having significant roles in apoptosis, cell cycle regulation and oncogenesis (Hosokawa et al., 2007; Li et al., 2008). Together this data suggests a likely role for KIAA0101 in DNA repair and in protection from UV-induced cell death.

Mutations

Note

Experimentally mutation I-A at position 65 and F-A at position 68 result in loss of PCNA binding (Yu et al., 2001). No other mutations have been described. Screening of colon tumour samples identified a polymorphism in the intronic region just prior to the start of exon 2 (982-15delT) (Simpson et al., 2006).

Implicated in

Hepatocellular carcinoma

Disease

KIAA0101 expression was proposed to promote growth advantage and hypoxic insult resistance and be associated with promoting cell proliferation (Yuan et al., 2007). KIAA0101 overexpression was associated with concomitant p53 mutation and vascular invasion (Yuan et al., 2007). This study suggested that high expression in hepatocellular carcinoma was indicative of tumour recurrence, metastatic potential and poor prognosis (Yuan et al., 2007). KIAA0101 was also reported to be downregulated in hepatocellular carcinoma (Guo et al., 2006). This study suggested that KIAA0101 had a growth inhibitory effect.

Astrocytomas

Disease

Grade IV (glioblastoma multiforme) astrocytomas had 5 times higher expression levels when compared to Grade I (pilocytic) astrocytomas suggesting that KIAA0101 abundance correlates with malignancy grade in human astrocytes (Marie et al., 2008).

Pancreatic cancer

Disease

Pancreatic cells overexpress KIAA0101 both at cDNA and protein level. Knock down of KIAA0101 by siRNA attenuated proliferation and DNA replication whereas overexpression enhanced cell growth in pancreatic cancer cell lines (Hosokawa et al., 2007).

Anaplastic thyroid carcinoma

Disease

Anaplastic thyroid carcinoma cell lines had significant overexpression of KIAA0101. Cell growth was inhibited by silencing KIAA0101 expression using siRNA. KIAA0101 may be oncogenic or cell growth-promoting but the mechanism for this is not understood (Mizutani et al., 2005).

Follicular lymphoma

Disease

High expression of KIAA0101 (along with CCNB1 (cyclin B1), CDC2, CDKN3A, CKS1B, ANP32E) was associated with better survival/response rate in a univariate analysis following CHOP (cyclophosphamide, vincristine, doxorubicin,

prednisone) chemotherapy for follicular lymphoma treatment. Identification of these proteins aims to develop a follicular lymphoma international prognostic index to aid in informing a successful treatment strategy (Bjorck et al., 2005).

Oncogenesis

This gene is thought to be oncogenic through modulation of DNA repair pathways via interaction with PCNA.

References

- Nagase T, Miyajima N, Tanaka A, Sazuka T, Seki N, Sato S, Tabata S, Ishikawa K, Kawarabayasi Y, Kotani H. Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. *DNA Res.* 1995;2(1):37-43
- Paunesku T, Mittal S, Protić M, Oryhon J, Korolev SV, Joachimiak A, Woloschak GE. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. *Int J Radiat Biol.* 2001 Oct;77(10):1007-21
- Yu P, Huang B, Shen M, Lau C, Chan E, Michel J, Xiong Y, Payan DG, Luo Y. p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. *Oncogene.* 2001 Jan 25;20(4):484-9
- Björck E, Ek S, Landgren O, Jerkeman M, Ehinger M, Björkholm M, Borrebaeck CA, Porwit-MacDonald A, Nordenskjöld M. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. *Blood.* 2005 Apr 1;105(7):2908-15
- Mizutani K, Onda M, Asaka S, Akaishi J, Miyamoto S, Yoshida A, Nagahama M, Ito K, Emi M. Overexpressed in anaplastic thyroid carcinoma-1 (OEATC-1) as a novel gene responsible for anaplastic thyroid carcinoma. *Cancer.* 2005 May 1;103(9):1785-90
- Guo M, Li J, Wan D, Gu J. KIAA0101 (OEACT-1), an expressionally down-regulated and growth-inhibitory gene in human hepatocellular carcinoma. *BMC Cancer.* 2006 Apr 29;6:109
- Simpson F, Lammerts van Bueren K, Butterfield N, Bennetts JS, Bowles J, Adolphe C, Simms LA, Young J, Walsh MD, Leggett B, Fowles LF, Wicking C. The PCNA-associated factor KIAA0101/p15(PAF) binds the potential tumor suppressor product p33ING1b. *Exp Cell Res.* 2006 Jan 1;312(1):73-85
- Collado M, Garcia V, Garcia JM, Alonso I, Lombardia L, Diaz-Uriarte R, Fernández LA, Zaballos A, Bonilla F, Serrano M. Genomic profiling of circulating plasma RNA for the analysis of cancer. *Clin Chem.* 2007 Oct;53(10):1860-3
- Hosokawa M, Takehara A, Matsuda K, Eguchi H, Ohigashi H, Ishikawa O, Shinomura Y, Imai K, Nakamura Y, Nakagawa H. Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. *Cancer Res.* 2007 Mar 15;67(6):2568-76
- van Bueren KL, Bennetts JS, Fowles LF, Berkman JL, Simpson F, Wicking C. Murine embryonic expression of the gene for the UV-responsive protein p15(PAF). *Gene Expr Patterns.* 2007 Jan;7(1-2):47-50
- Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH, Hsu HC. Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. *Clin Cancer Res.* 2007 Sep 15;13(18 Pt 1):5368-76
- Li K, Ma Q, Shi L, Dang C, Hong Y, Wang Q, Li Y, Fan W, Zhang L, Cheng J. NS5ATP9 gene regulated by NF-kappaB signal pathway. *Arch Biochem Biophys.* 2008 Nov 1;479(1):15-9
- Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG Jr, Toledo S, Moreira-Filho CA, Zago MA, Simpson AJ, Caballero OL. Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. *Int J Cancer.* 2008 Feb 15;122(4):807-15
- Shi L, Zhang SL, Li K, Hong Y, Wang Q, Li Y, Guo J, Fan WH, Zhang L, Cheng J. NS5ATP9, a gene up-regulated by HCV NS5A protein. *Cancer Lett.* 2008 Feb 8;259(2):192-7
- Turchi L, Fareh M, Aberdam E, Kitajima S, Simpson F, Wicking C, Aberdam D, Virolle T. ATF3 and p15PAF are novel gatekeepers of genomic integrity upon UV stress. *Cell Death Differ.* 2009 May;16(5):728-37
- Miller WR, Larionov A. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. *Breast Cancer Res.* 2010;12(4):R52

This article should be referenced as such:

Joseph S, Hu L, Simpson F. KIAA0101 (KIAA0101). *Atlas Genet Cytogenet Oncol Haematol.* 2011; 15(11):965-967.
